Use of hydroxychloroquine and interferon alpha-2b for the prophylaxis of COVID-19
- 1 November 2020
- journal article
- letter
- Published by Elsevier BV in Medical Hypotheses
- Vol. 144, 109802
- https://doi.org/10.1016/j.mehy.2020.109802
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases
This publication has 16 references indexed in Scilit:
- Coronavirus Cell Entry Occurs through the Endo-/Lysosomal Pathway in a Proteolysis-Dependent MannerPLoS Pathogens, 2014
- Chloroquine is a potent inhibitor of SARS coronavirus infection and spreadVirology Journal, 2005
- Mechanism of the interferon alpha response against hepatitis C virus repliconsVirology, 2004
- The potential place of chloroquine in the treatment of HIV-1-infected patientsJournal of Clinical Virology, 2001
- Clinical Pharmacokinetics and Metabolism of ChloroquineClinical Pharmacokinetics, 1996
- Ocular safety of hydroxychloroquine.1991
- Diagnosis of Chloroquine Cardiomyopathy by Endomyocardial BiopsyThe New England Journal of Medicine, 1987
- Prevention of Experimental Coronavirus Colds with Intranasal -2b InterferonThe Journal of Infectious Diseases, 1986
- Disposition of chloroquine in man after single intravenous and oral doses.British Journal of Clinical Pharmacology, 1983
- CHLOROQUINE: A REVIEWRheumatology, 1976